Results 41 to 50 of about 10,873 (203)

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury

Frontiers in Pharmacology, 2021
The therapeutic indices (TIs) and efficacy of the non-steroidal mineralocorticoid receptor antagonist (MRA) KBP-5074 and steroidal MRA eplerenone were evaluated in a uninephrectomized Sprague Dawley rat model of aldosterone-mediated renal disease. In two
Frédéric Jaisser, Xiaojuan Tan, Shuangshuang Chi, Jinrong Liu, Ping Wang, Mark Bush, Vincent Benn, Y. Fred Yang, Jay Zhang   +8 more
doaj   +1 more source

Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations [PDF]

, 2012
Background—Eplerenone is known to reduce time to first hospitalization for heart failure or cardiovascular death in patients with heart failure and mild symptoms.
Swedberg, Karl, Krum, H., Rogers, Jennifer K, Zannad, Faiez, Vincent, J., Pocock, S.J., Zannad, F., Pitt, B., McMurray, John JV, McMurray, J.J.V., Shi, H., Vincent, John, van Veldhuisen, Dirk J., Rogers, J.K., Rogers, Jennifer K., Krum, Henry, van Veldhuisen, D.J., Pocock, Stuart J, van Veldhuisen, Dirk J, McMurray, John J. V., Shi, Harry, Pocock, Stuart J., Pitt, Bertram, Swedberg, K., Pocock, S. J., Swedberg, Karl,, van Veldhuisen, D. J., McMurray, J. J., Rogers, J. K.   +28 more
core   +1 more source

Hepatoprotective effect of the selective mineralocorticoid receptor antagonist, eplerenone against carbon tetrachloride-induced liver injury in rats

Annals of Hepatology, 2012
Background. Eplerenone is a selective mineralocorticoid receptor (MR) antagonist, and its potential protective role in cardiovascular injury has been reported by several studies. However, whether and how this drug can ameliorate hepatic injury in rats is
Ashraf Taye, Ihab T. Abdel-Raheem
doaj   +1 more source

Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI RCT

Efficacy and Mechanism Evaluation, 2021
Background: In chronic central serous chorioretinopathy, fluid accumulates in the subretinal space and causes permanent vision loss in ≈ 30% of patients. There is no definitive treatment.
Andrew Lotery, Sobha Sivaprasad, Abby O’Connell, Rosie A Harris, Lucy Culliford, Angela Cree, Savita Madhusudhan, Helen Griffiths, Lucy Ellis, Usha Chakravarthy, Tunde Peto, Chris A Rogers, Barnaby C Reeves   +12 more
doaj   +1 more source

Eplerenone in patients with systolic heart failure and mild symptoms [PDF]

, 2010
BACKGROUND: Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and heart failure after myocardial infarction. We evaluated the effects of eplerenone in patients with chronic systolic heart failure
Swedberg, Karl, Krum, H., Faiez Zannad, Pocock, S. J., Zannad, Faiez, John Vincent, Vincent, J., Pocock, S.J., Zannad, F., Pitt, B., McMurray, John JV, EMPHASIS-HF Study Group, McMurray, J.J.V., Shi, H., Henry Krum, Vincent, John, van Veldhuisen, Dirk J., John J.V. McMurray, Stuart J. Pocock, Karl Swedberg, Bertram Pitt, Krum, Henry, van Veldhuisen, D.J., Swedberg, Karl,, Pocock, Stuart J, Harry Shi, van Veldhuisen, D. J., van Veldhuisen, Dirk J, McMurray, J. J., McMurray, John J. V., Shi, Harry, Pocock, Stuart J., Dirk J. van Veldhuisen, Pitt, Bertram, Swedberg, K., Zannad F, EMPHASIS HF Study Group, MONTE, INES PAOLA, McMurray JJ, Krum H   +39 more
core   +1 more source

Eplerenone as a treatment for resistant hypertension in pregnancy

, 2019
Mineralocorticoid receptor antagonists are highly effective in the management of resistant hypertension and primary hyperaldosteronism. Recent studies demonstrate that mineralocorticoid receptor antagonists significantly reduce blood pressure, severity ...
Morton, Adam, Gehlert, Jessica
core   +1 more source

Cost effectiveness of eplerenone in patients with chronic heart failure [PDF]

, 2014
BACKGROUND: Chronic heart failure (CHF) remains an important cause of morbidity and mortality worldwide. Currently, there are no cost-effectiveness studies of eplerenone use in patients with New York Heart Association (NYHA) class II CHF.
Pasupathi, K, Krum, H, Ademi, Z, Liew, D
core   +1 more source

Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. [PDF]

PLoS ONE, 2018
Excess mineralocorticoid receptor (MR) activation promotes target organ dysfunction, vascular injury and fibrosis. MR antagonists like eplerenone are used for treating heart failure, but their use is limited due to the compound class-inherent ...
Krister Bamberg, Ulrika Johansson, Karl Edman, Lena William-Olsson, Susanna Myhre, Anders Gunnarsson, Stefan Geschwindner, Anna Aagaard, Anna Björnson Granqvist, Frédéric Jaisser, Yufeng Huang, Kenneth L Granberg, Rasmus Jansson-Löfmark, Judith Hartleib-Geschwindner   +13 more
doaj   +1 more source

Structures of AZD9977 and eplerenone.

, 2018
Structures of AZD9977 ((S)-2-(7-Fluoro-4-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-3-yl)-N-methylacetamide) and eplerenone.
Anna Björnson Granqvist (4885225), Stefan Geschwindner (840623), Karl Edman (2572066), Anna Aagaard (3632740), Rasmus Jansson-Löfmark (4885222), Ulrika Johansson (217525), Frédéric Jaisser (4885231), Kenneth L. Granberg (4885228), Judith Hartleib-Geschwindner (4885219), Susanna Myhre (4662763), Yufeng Huang (782683), Lena William-Olsson (4885234), Krister Bamberg (583828), Anders Gunnarsson (1454497)   +13 more
core   +1 more source

Eplerenone Survival Benefits in Heart Failure Patients Post-Myocardial Infarction [PDF]

, 2012
Reduced left ventricular ejection fraction (≤40%) and/or signs of clinical heart failure after acute myocardial infarction (AMI) are associated with a relatively high incidence of mortality and hospitalization for heart failure.
Prappa, Efstathia
core   +1 more source